FDA Finds “Comfort Level” With Using Medicare Data For Sentinel Initiative
Executive Summary
FDA research into the clinical accuracy and stability over time of Medicare claims data has shown it could be a reliable source of information for active product safety surveillance, according to FDA’s Judy Racoosin, scientific lead for the Sentinel Initiative within the Center for Drug Evaluation and Research.
You may also be interested in...
BI’s Pradaxa Gets Mixed Reviews In Postmarketing Studies
Two observational studies of Medicare patients reach different conclusions on Pradaxa bleeding rates, but FDA says risk/benefit profile of drug has not changed.